Selecta Biosciences Inc. (NASDAQ:SELB) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $30.00.
A number of equities analysts recently commented on SELB shares. Zacks Investment Research cut Selecta Biosciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 21st. BidaskClub upgraded Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Canaccord Genuity reiterated a “buy” rating and set a $30.00 price target on shares of Selecta Biosciences in a report on Thursday, January 18th. Mizuho started coverage on Selecta Biosciences in a report on Monday, February 26th. They set a “buy” rating and a $30.00 price target for the company. Finally, ValuEngine cut Selecta Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd.
Selecta Biosciences stock traded up $0.25 during midday trading on Friday, reaching $11.96. 183,900 shares of the company’s stock were exchanged, compared to its average volume of 298,823. Selecta Biosciences has a 52 week low of $11.54 and a 52 week high of $11.65. The company has a debt-to-equity ratio of 0.51, a quick ratio of 7.20 and a current ratio of 7.20. The stock has a market capitalization of $257.25 million, a P/E ratio of -3.74 and a beta of -3.65.
Several large investors have recently modified their holdings of SELB. Bank of New York Mellon Corp boosted its holdings in shares of Selecta Biosciences by 26.6% during the third quarter. Bank of New York Mellon Corp now owns 41,020 shares of the company’s stock worth $748,000 after acquiring an additional 8,620 shares during the period. Schwab Charles Investment Management Inc. boosted its holdings in shares of Selecta Biosciences by 50.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 29,600 shares of the company’s stock worth $541,000 after acquiring an additional 9,900 shares during the period. Wasatch Advisors Inc. boosted its holdings in shares of Selecta Biosciences by 100.6% during the fourth quarter. Wasatch Advisors Inc. now owns 246,618 shares of the company’s stock worth $2,419,000 after acquiring an additional 123,695 shares during the period. SG Americas Securities LLC bought a new stake in shares of Selecta Biosciences in the fourth quarter valued at approximately $145,000. Finally, Alps Advisors Inc. bought a new stake in shares of Selecta Biosciences in the fourth quarter valued at approximately $243,000. Institutional investors own 48.24% of the company’s stock.
About Selecta Biosciences
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.